In highly lethal type of leukemia, cancer gene predicts treatment response
Thursday, November 24, 2016 - 15:01
in Health & Medicine
Patients with the most lethal form of acute myeloid leukemia (AML) – based on genetic profiles of their cancers – typically survive for only four to six months after diagnosis, even with aggressive chemotherapy. But new research indicates that such patients, paradoxically, may live longer if they receive a milder chemotherapy drug.